Andrew B. Lassman

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial

  Journal of Clinical Oncology · 2026-05-07

• Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial

  Journal of Clinical Oncology · 2026-04-14 · 1 citations

• Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery

  Journal of Clinical Oncology · 2026-01-16 · 1 citations

• Supplementary Figures S1-S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S2 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S5 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• 10001-NT-1 ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

  Neuro-Oncology Advances · 2025-12-01

• STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma

  Journal of Clinical Oncology · 2025-12-01 · 1 citations

• TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

  Neuro-Oncology · 2025-11-01 · 1 citations

• INNV-17. Diagnostic Performance and Prognostic Value of the G8 Screening Tool in Older Adults with Newly Diagnosed Glioblastoma, IDH Wild-Type

  Neuro-Oncology · 2025-11-01

• IMG-129. Combination of advanced imaging, <i>MGMT</i> status and time since chemoradiation to optimize distinction between early progression and pseudoprogression in glioblastoma

  Neuro-Oncology · 2025-11-01

• CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA

  Neuro-Oncology · 2025-11-01

• OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209

  Neuro-Oncology · 2025-10-01